Clinical Impact of Upfront Dose Reduction of the First Cycle of First‐Line Treatments on Safety and Survival in Elderly Patients With Non‐Small Cell Lung Cancer

Documenti analoghi

• The Effectiveness of Afatinib as First‐Line Treatment in Vietnamese Patients With EGFR‐Mutant Non–Small Cell Lung Cancer and Brain Metastases
  di: Thai Van Pham, et al.
  Pubblicazione: (2024)
• Inflammation‐Based Prognostication in Extensive‐Stage Small Cell Lung Cancer in the First‐Line Setting: The Advanced Lung Inflammation Index and the Others
  di: Erdoğan Selçuk Şeber, et al.
  Pubblicazione: (2025)
• Larotrectinib in Adjuvant and First‐Line Treatment for Metastatic NTRK Fusion Colon Cancer
  di: Alexander Y. Volkov, et al.
  Pubblicazione: (2026)
• Factors Associated With Long‐Term Survivors With Epidermal Growth Factor Receptor Positive Non‐Small Cell Lung Cancer Treated With First or Second‐Generation Tyrosine Kinase Inhibitors: A Canadian Multi‐Center Cohort
  di: Heather Halperin, et al.
  Pubblicazione: (2026)
• Prolonged Survival in Anaplastic Thyroid Cancer: Insights From Multi‐Modal Treatment
  di: Bella Nguyen, et al.
  Pubblicazione: (2025)